Carlota Recio

List of Publications by Year
in descending order

24	918	430754	642610
papers	citations	18	23
		h-index	g-index

25	25	25	1583
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Mevalonate Pathway, a Metabolic Target in Cancer Therapy. Frontiers in Oncology, 2021, 11, 626971.	1.3	64
2	JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. Biomedicine and Pharmacotherapy, 2021, 144, 112330.	2.5	4
3	Characterisation of endogenous Galectin-1 and -9 expression in monocyte and macrophage subsets under resting and inflammatory conditions. Biomedicine and Pharmacotherapy, 2020, 130, 110595.	2.5	17
4	A Biased Agonist at Immunometabolic Receptor GPR84 Causes Distinct Functional Effects in Macrophages. ACS Chemical Biology, 2019, 14, 2055-2064.	1.6	27
5	Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology. Oncogene, 2019, 38, 4657-4668.	2.6	24
6	SOCS1-targeted therapy ameliorates renal and vascular oxidative stress in diabetes via STAT1 and PI3K inhibition. Laboratory Investigation, 2018, 98, 1276-1290.	1.7	45
7	The Role of Metabolite-Sensing G Protein-Coupled Receptors in Inflammation and Metabolic Disease. Antioxidants and Redox Signaling, 2018, 29, 237-256.	2.5	13
8	In Vitro Migration Assays. Methods in Molecular Biology, 2018, 1784, 197-214.	0.4	4
9	Activation of the Immune-Metabolic Receptor GPR84 Enhances Inflammation and Phagocytosis in Macrophages. Frontiers in Immunology, 2018, 9, 1419.	2.2	110
10	Nrf2 Activation Provides Atheroprotection in Diabetic Mice Through Concerted Upregulation of Antioxidant, Anti-inflammatory, and Autophagy Mechanisms. Frontiers in Pharmacology, 2018, 9, 819.	1.6	59
11	Interplay between HSP90 and Nrf2 pathways in diabetes-associated atherosclerosis. Clínica E Investigación En Arteriosclerosis, 2017, 29, 51-59.	0.4	21
12	Interplay between HSP90 and Nrf2 pathways in diabetes-associated atherosclerosis. Clínica E Investigación En Arteriosclerosis (English Edition), 2017, 29, 51-59.	0.1	0
13	Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 575-585.	3.0	54
14	Absence of the Non-Signalling Chemerin Receptor CCRL2 Exacerbates Acute Inflammatory Responses In Vivo. Frontiers in Immunology, 2017, 8, 1621.	2.2	18
15	Cannabinoid Receptor 2 Modulates Neutrophil Recruitment in a Murine Model of Endotoxemia. Mediators of Inflammation, 2017, 2017, 1-15.	1.4	24
16	The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease. Frontiers in Pharmacology, 2016, 7, 526.	1.6	77
17	Acute exposure to apolipoprotein A1 inhibits macrophage chemotaxis in vitro and monocyte recruitment in vivo. ELife, 2016, 5, .	2.8	50
18	Gene delivery of suppressors of cytokine signaling (SOCS) inhibits inflammation and atherosclerosis development in mice. Basic Research in Cardiology, 2015, 110, 8.	2.5	28

#	Article	IF	Citations
19	Targeting HSP90 Ameliorates Nephropathy and Atherosclerosis Through Suppression of NF-κB and STAT Signaling Pathways in Diabetic Mice. Diabetes, 2015, 64, 3600-3613.	0.3	64
20	Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes. Diabetologia, 2015, 58, 1656-1667.	2.9	40
21	Suppressor of Cytokine Signaling 1–Derived Peptide Inhibits Janus Kinase/Signal Transducers and Activators of Transcription Pathway and Improves Inflammation and Atherosclerosis in Diabetic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1953-1960.	1.1	59
22	Peptide Inhibitor of NF-κB Translocation Ameliorates Experimental Atherosclerosis. American Journal of Pathology, 2013, 182, 1910-1921.	1.9	52
23	Gene Deficiency in Activating Fcγ Receptors Influences the Macrophage Phenotypic Balance and Reduces Atherosclerosis in Mice. PLoS ONE, 2013, 8, e66754.	1.1	25
24	Fcγ Receptor Deficiency Attenuates Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1518-1527.	3.0	37